PMID- 15199601
OWN - NLM
STAT- MEDLINE
DCOM- 20040707
LR  - 20190917
IS  - 0735-7907 (Print)
IS  - 0735-7907 (Linking)
VI  - 22
IP  - 2
DP  - 2004
TI  - Prognostic value of PCNA and mutant p53 expression in laryngeal squamous cell 
      carcinoma.
PG  - 195-202
AB  - The objective of this study was to investigate the prognostic significance of 
      p53, and proliferative cell nuclear antigen (PCNA) in laryngeal squamous cell 
      carcinoma (LSCC). Sixty pathologic specimens from the patients with LSCC were 
      examined for the expression of the p53 and PCNA, with complete follow-up data. 
      Sixty-three percent of the cases displayed nuclear p53 overexpression. There was 
      a correlation between p53 overexpression and histological grades (p = 0.03), and 
      localization site (p = 0.05). Median of PCNA index was 42.2 (range 5.9 to 85.2). 
      There was no difference between the p53 overexpression group and the normal group 
      in proliferative activity determined by PCNA (p = 0.73). In univariate analyses, 
      localization site, grade, stage, invasion pattern, lymph node status, were 
      significant factors in estimating disease free survival (DFS). Grade was the most 
      important factor affecting recurrence (p = 0.002). In multivariate analyses, 
      grade was the only significant predictor for DFS (p = 0.001). Grade (p = 0.001) 
      and invasion pattern (p = 0.03) were found to be significant predictors of 
      overall survival. In conclusion, the histological grade was the most reliable 
      important prognostic factor. Further studies are necessary to facilitate 
      understanding of the mechanisms of laryngeal carcinogenesis.
FAU - Buyukbayram, Huseyin
AU  - Buyukbayram H
AD  - Department of Pathology, Faculty of Medicine, Dicle University, Diyarbakir, 
      Turkey. husram@dicle.edu.tr
FAU - Cureoglu, Sebahattin
AU  - Cureoglu S
FAU - Arslan, Adem
AU  - Arslan A
FAU - Isikakdogan, A Rahman
AU  - Isikakdogan AR
LA  - eng
PT  - Journal Article
PL  - England
TA  - Cancer Invest
JT  - Cancer investigation
JID - 8307154
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Proliferating Cell Nuclear Antigen)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Adult
MH  - Carcinoma, Squamous Cell/*genetics/*pathology
MH  - DNA Mutational Analysis
MH  - DNA, Neoplasm
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - *Gene Expression Profiling
MH  - *Genes, p53
MH  - Humans
MH  - Immunohistochemistry
MH  - Laryngeal Neoplasms/*genetics/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Proliferating Cell Nuclear Antigen/*analysis
MH  - Tumor Suppressor Protein p53/*biosynthesis
EDAT- 2004/06/18 05:00
MHDA- 2004/07/09 05:00
CRDT- 2004/06/18 05:00
PHST- 2004/06/18 05:00 [pubmed]
PHST- 2004/07/09 05:00 [medline]
PHST- 2004/06/18 05:00 [entrez]
AID - 10.1081/cnv-120030207 [doi]
PST - ppublish
SO  - Cancer Invest. 2004;22(2):195-202. doi: 10.1081/cnv-120030207.